Loading…
← CockpitCompetitor Analysis › 2698.HK Softcare LimitedOpen in the cockpit ↗

Softcare Limited2698.HKCompetitor analysis, valuation and peers

Hong Kong · HKD·Consumer Staples›Household/Personal Care

Maker of infant diapers, training pants and feminine hygiene products focused on Africa, Latin America and Central Asia.

≈ An emerging-markets Kimberly-Clark, Africa-focusedMomentum strong 76
Mkt cap
$2.20B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$5.10M
20-day average traded
Fwd P/E
14.4×
forward earnings
ROIC−WACC
+34.7 pp
WACC 11.9%
Hurdle
-12 pp
Req g minus delivered
Next earnings
124 days
22 Mar 2027
Close · HKDHK$28.28
1D-1.1%
1W+0.1%
1M+7.5%
3M-11.4%
6M+4.9%
YTD-12.6%
1Y-14.3%
ATR %4.8%
52w lowhigh21.2% off high

What Softcare does

Maker of infant diapers, training pants and feminine hygiene products focused on Africa, Latin America and Central Asia.

In one line: An emerging-markets Kimberly-Clark, Africa-focused.

Products and services

  • Infant diapers
  • Training pants
  • Feminine hygiene products

Customers

  • Retailers and consumers across Africa, Latin Ameri

Where it sits in the supply chain

  • Consumer Staples
  • Personal/household care
  • Diapers & feminine hygiene

What could go right

  • Rising diaper/hygiene-product penetration in Africa and emerging markets

What could go wrong

  • Emerging-market currency/economic volatility
  • Raw-material (pulp, resin) cost swings

Moat: narrow (brand, distribution, scale). Roughly #2 share in Africa's diaper and sanitary-napkin markets, built on distribution across many emerging markets.

Headquarters: Hong Kong / Africa operations · Employees: 2,906

Named competitors

Softcare at a glance

Size Softcare (2698.HK) is a Hong Kong Consumer Staples company (Household/Personal Care) with a market value of $2.20B, the 390th largest of 885 Hong Kong companies the cockpit tracks. Shares closed at HK$28.28 on 18 Nov 2026.

Performance Over six months the shares gained 4.9%, against -4.7% for the median peer and -14.0% for the Hong Kong market (cap-weighted) — 9th highest of 21 in its peer set.

Growth Revenue grew 24.8% over the last twelve months (peer median +4.3%); the operating margin is 25.2% (peer median 10.5%).

Valuation It trades at 14.4× forward earnings against a peer median of 22.2× (6th cheapest of 21).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -12 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 34.7 points above its cost of capital (11.9% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

10012021 May 202621 Aug 202618 Nov 20262698.HK 108Peer median 97
Six months, rebased to 100: Softcare against the median of its 20 peers (local-currency closes).

Softcare financials

Reported figures in HKD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenuen/aHK$4.42BHK$3.55BHK$3.22BHK$2.50B
Revenue growth—+25%+10%+29%—
Gross profitn/aHK$1.59BHK$1.25BHK$1.12BHK$571M
EBITDAn/aHK$1.13BHK$974MHK$807MHK$338M
Net incomen/aHK$945MHK$742MHK$506MHK$144M
Free cash flown/aHK$504MHK$598MHK$676M-HK$194M
Capital expendituren/aHK$408MHK$256MHK$67.6MHK$246M
Total debtn/aHK$165MHK$18.9MHK$754MHK$1.33B

Quarterly statements and history in the cockpit →

Softcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-20%0%+20%+40%-10%0%+10%492269931618904927PGHH2367EMAMILTDENR192820300888GILLETTE795605190030095760360560398360031500279030137149672698.HK6-month return →1-month return →
Up and to the right = strong over both horizons. Softcare is the large dot.

Fundamentals: revenue growth against valuation

0%+10%+20%20×40×492269931618904927PGHH2367EMAMILTDENR192820300888GILLETTE795605190030095760360560398360031500279030137149672698.HKRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Softcare is the large dot.

Capital: growth delivered against growth the price implies

0%+20%0%20%1618904927PGHH2367EMAMILTDENR300888GILLETTE3009576036056003153013712698.HKGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Softcare is the large dot.

Softcare competitors and peer comparison

Head to head with its named competitors (2698.HK vs 1044.HK vs KMB vs PG)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Softcare 2698.HK$2.20B+5%+25%25%14.4×9.1%
Hengan Int'l 1044.HK$3.27B-12%+2%11%9.1×-8.2%
Kimberly-Clark KMB$65.8B+11%-8%14%15.2×5.1%
Procter & Gamble PG$395B+20%+4%24%24.1×0.5%
Unicharm 8113.T$13.0B+20%+2%11%26.9×0.1%

How Softcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Softcare against its 20 peers (data as of 18 Nov 2026)
Measure2698.HKPeer medianRank in peer set
1-month return+7.5%-2.0%6th highest of 21
6-month return+4.9%-4.7%9th highest of 21
Distance from 52-week high-21.2%-26.2%8th highest of 21
Revenue growth (TTM)+24.8%+4.3%3rd highest of 21
Operating margin25.2%10.5%3rd highest of 21
Forward P/E14.4×22.2×6th cheapest of 21
Growth the price implies (Req g, 7 yrs)9.1%-1.8%6th most demanding of 17
Growth delivered (Del g)+20.9%+2.8%3rd highest of 17
Hurdle (Req g minus delivered)-11.8 pp-2.0 pp5th least demanding of 17
ROIC minus cost of capital+34.7 pp+5.1 pp3rd highest of 20
EV / EBITDA12.5×10.3×6th most expensive of 14
Net debt / EBITDA-2.8×-1.8×3rd least indebted of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Softcare 2698.HKHong Kong$2.20B+5%+25%25%14.4×9.1%+20.9%
KOSE 4922.TJapan$2.16B+16%+4%5%29.9×n/an/a
Blue Moon 6993.HKHong Kong$2.07B-4%-2%-2%103.3×n/an/a
Kolmar Korea 161890.KSSouth Korea$2.05B+14%+16%10%14.3×-1.6%+15.5%
Pola Orbis 4927.TJapan$2.04B+15%+1%11%30.6×-2.0%-0.7%
Procter & Gamble Hygiene & Health Care PGHH.NSIndia$2.37B-30%-2%24%27.0×21.2%+7.4%
Giant Biogene 2367.HKHong Kong$2.47B-32%-10%32%8.6×-10.7%+34.9%
Emami EMAMILTD.NSIndia$1.94B-5%+13%20%23.4×21.5%+5.6%
Energizer ENRUnited States$1.94B+71%0%17%9.1×-5.1%-0.5%
Cosmax 192820.KSSouth Korea$2.51B+53%+25%8%18.8×n/an/a
Winner Medical 300888.SZChina$2.53B-6%+4%11%19.9×-5.2%-2.6%
Gillette India GILLETTE.NSIndia$2.53B-5%+8%28%37.1×14.9%+13.0%
Pigeon 7956.TJapan$1.76B+26%+8%13%27.9×-2.4%+1.9%
LG H&h 051900.KSSouth Korea$2.81B-14%-3%3%23.1×-4.6%-4.1%
Yunnan Botanee Bio-Technology 300957.SZChina$1.69B-33%+7%9%19.1×2.6%+15.3%
Proya Cosmetics 603605.SSChina$2.87B-13%+2%13%10.9×-5.3%+23.1%
Guangdong Marubi Biotechnology 603983.SSChina$1.62B+9%-6%2%45.5×n/an/a
Shanghai Jahwa United 600315.SSChina$1.61B-15%+9%2%15.4×15.3%-2.1%
AMOREPACIFIC 002790.KSSouth Korea$1.61B+2%+9%9%8.5×-5.7%-1.3%
Harbin Fuerjia Technology 301371.SZChina$1.51B-39%+28%20%21.4×7.5%+3.6%
Kobayashi Pharmaceutical 4967.TJapan$3.25B+20%+2%6%48.7×18.0%+1.9%

Questions

Who are Softcare's main competitors?
Named competitors: Hengan International (1044.HK), Kimberly-Clark (KMB), Procter & Gamble (PG), Unicharm (8113.T). The cockpit's measured peer set (industry) also includes KOSE (4922.T), Blue Moon (6993.HK), Kolmar Korea (161890.KS), Pola Orbis (4927.T), Procter & Gamble Hygiene & Health Care (PGHH.NS), Giant Biogene (2367.HK).
Is Softcare expensive compared with its peers?
On forward p/e it trades at 14.4× against a peer median of 22.2×, 6th cheapest of 21 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -12 pp: the price already allows for a slowdown.
How has Softcare stock performed?
Over six months to 18 Nov 2026 the shares returned +4.9% against -4.7% for the median peer; over one year -14.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.